Chemesis International Inc. - günstige Cannabis-Aktie (Seite 268)
eröffnet am 05.09.18 16:13:54 von
neuester Beitrag 06.03.24 18:33:05 von
neuester Beitrag 06.03.24 18:33:05 von
Beiträge: 2.751
ID: 1.287.816
ID: 1.287.816
Aufrufe heute: 0
Gesamt: 352.583
Gesamt: 352.583
Aktive User: 0
ISIN: CA75867L2066 · WKN: A407GC
0,1300
EUR
+173,68 %
+0,0825 EUR
Letzter Kurs 28.03.24 Lang & Schwarz
Werte aus der Branche Rohstoffe
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2500 | +66,67 | |
0,9500 | +42,86 | |
1,3900 | +29,94 | |
0,6500 | +20,37 | |
210,35 | +18,24 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,6200 | -7,46 | |
1,7300 | -8,95 | |
173,10 | -9,84 | |
0,6500 | -18,75 | |
0,5900 | -35,87 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 58.763.281 von Nico1977 am 21.09.18 16:23:06
Ich habe mal eine bescheidene Frage, Aurora, Canopy usw. haben mittlerweile eine Marktkapitalisierung jenseits von 5 mrd. Dollar.
Haltet ihr es für
Möglich, dass chem es auch schafft in diese Region zu kommen? Das würde einen massiven Ausbruch bedeuten? Ist zwar ein Wunschvorstellung aber ist nur eines Interesse. Ich halte momentan 50k Aktien an Chem.
Ausbruch möglich?
Hallo, Ich habe mal eine bescheidene Frage, Aurora, Canopy usw. haben mittlerweile eine Marktkapitalisierung jenseits von 5 mrd. Dollar.
Haltet ihr es für
Möglich, dass chem es auch schafft in diese Region zu kommen? Das würde einen massiven Ausbruch bedeuten? Ist zwar ein Wunschvorstellung aber ist nur eines Interesse. Ich halte momentan 50k Aktien an Chem.
Antwort auf Beitrag Nr.: 58.762.801 von bohrmeister am 21.09.18 15:45:39so ein Quatsch, wo siehst du das denn
!
Dieser Beitrag wurde von MadMod moderiert. Grund: themenfremder Inhalt!
Dieser Beitrag wurde von MadMod moderiert. Grund: themenfremder Inhalt!
Dieser Beitrag wurde von MadMod moderiert. Grund: themenfremder Inhalt
Eine kleine Beispielrechnung
Wenn man als Beispiel von einem Gewinn von 10 Mio. für 2019 ausgeht (CSI erwartet laut Präsentaion deutlich mehr !), wäre das auf sämtliche Aktien (67.247.095) gerechnet ein Gewinn von etwa 0,15 pro Aktie.
Bei einem Kurs von 2 $ wäre das KGV dann bei 13
Und ein KGV von 13 ist für eine Wachstumsbranche (wie Cannabis, Big-Data, oder Krypto) sehr günstig. Ein KGV von 20 wäre durchaus gerechtfertigt. Das wären dann 3 $.
Nur zur Info. Laut Präsentation rechnet CSI im Jahr 2 mit einem "net income" in Kalifornien von 22 Mio. $.
Wenn man als Beispiel von einem Gewinn von 10 Mio. für 2019 ausgeht (CSI erwartet laut Präsentaion deutlich mehr !), wäre das auf sämtliche Aktien (67.247.095) gerechnet ein Gewinn von etwa 0,15 pro Aktie.
Bei einem Kurs von 2 $ wäre das KGV dann bei 13
Und ein KGV von 13 ist für eine Wachstumsbranche (wie Cannabis, Big-Data, oder Krypto) sehr günstig. Ein KGV von 20 wäre durchaus gerechtfertigt. Das wären dann 3 $.
Nur zur Info. Laut Präsentation rechnet CSI im Jahr 2 mit einem "net income" in Kalifornien von 22 Mio. $.
Antwort auf Beitrag Nr.: 58.761.241 von brettonwoods am 21.09.18 13:27:43
Gut möglich, dass es zu Börsenbeginn oder zwischendurch Gewinnmitnahmen gibt. Nach dem Kursanstieg wäre dies nicht überraschend. Zum Börsenschluss rechne dann aber wieder mit einem Kursanstieg. Also ein Verlauf wie gestern. Der Grund ist eben der extrem niedrige reale Freefloat. Wenn weiterhin derzeit 75-80% oder mehr Aktien in festen Händen liegen, dann bleiben nicht mehr viele handelbare Aktien übrig. Und wenn der gesamte Cannabis-Markt, so wie gestern, positiv gestimmt ist, dann ist ein Kursanstieg recht wahrscheinlich. Die aufkommende Phantasie und Hoffnung durch die nur noch 3,5 Wochen bis zur Legalisierung in Kanada tun ihr übriges.
Ich persönlich weiß aktuell nicht, wann ich verkaufe oder zumindest teilverkaufe. Ich habe derzeit kein Kursziel.
Zitat von brettonwoods: bin mal gespannt, ob in Kanada dann heute mal ein paar Gewinnmitnahmen folgen... so zum Wochenende halt
Gut möglich, dass es zu Börsenbeginn oder zwischendurch Gewinnmitnahmen gibt. Nach dem Kursanstieg wäre dies nicht überraschend. Zum Börsenschluss rechne dann aber wieder mit einem Kursanstieg. Also ein Verlauf wie gestern. Der Grund ist eben der extrem niedrige reale Freefloat. Wenn weiterhin derzeit 75-80% oder mehr Aktien in festen Händen liegen, dann bleiben nicht mehr viele handelbare Aktien übrig. Und wenn der gesamte Cannabis-Markt, so wie gestern, positiv gestimmt ist, dann ist ein Kursanstieg recht wahrscheinlich. Die aufkommende Phantasie und Hoffnung durch die nur noch 3,5 Wochen bis zur Legalisierung in Kanada tun ihr übriges.
Ich persönlich weiß aktuell nicht, wann ich verkaufe oder zumindest teilverkaufe. Ich habe derzeit kein Kursziel.
Data Shows the Global Medical Cannabis Market is Set to Reach USD 28 Billion by 2024
C.CSI, C.MMEN, C.ICAN, CNAB, CBSHP | 1 day ago
FinancialBuzz.com News Commentary
PR Newswire
NEW YORK, September 19, 2018
NEW YORK, September 19, 2018 /PRNewswire/ --
According to a report provided by Energias Market Research, the global medical cannabis market is projected to increase in value from USD 8.28 Billion in 2017 to USD 28.07 Billion in 2024 and at a CAGR of 19.1% from 2018 to 2024. There are many significant developments that help increase the growth rate of the market, such as the increasing acknowledgment of medicinal benefits and higher demand for cannabis in the treatment of various diseases, as well as growing research and development investments. The data also shows that sales of cannabis products for recreational use are also likely to rise as California's new laws regarding recreational sales went into effect earlier this year. Chemesis International Inc. (OTC: CADMF), MedMen Enterprises Inc. (OTC: MMNFF), Integrated Cannabis Company, Inc. (OTC: ICNAF), United Cannabis Corporation (OTC: CNAB), Cannabics Pharmaceuticals Inc. (OTC: CNBX)
Canada had recently passed a nationwide legalization of recreational cannabis use, following Uruguay to become the second country to do so. According to CBC, Canada is one of only two countries, besides the Netherlands, that exports cannabis products, which allows companies in Canada to gain instant revenue from recent medical cannabis legalizations in more than 20 countries. CBC reported that the "offerings in today's Canada medical marijuana market differ little from those used recreationally - the smokable plant and, more recently, oil extracts. More than 70 companies have licenses from the federal drug regulator, Health Canada, to cultivate, produce and sell medical marijuana, with more than half those licenses granted in 2017 or 2018."
Chemesis International Inc. (OTC: CADMF) is also listed on the Canadian Securities Exchange under the ticker (CSE: CSI). Earlier last week, the Company announced, "the opening of its wholly owned subsidiary Chemesis Latin America. Through this subsidiary, the Company is exploring and completing advanced due diligence on opportunities for cultivation, production and export from the Latin American market. The Company believes it will be able to quickly gain market share in Latin America through the use of its networks and existing expertise.
Chemesis' long-term growth strategy is focused on international expansion. Globally, regulation changes are occurring for both medical and recreational cannabis, and as these changes occur, Chemesis intends to be a first mover by leveraging its existing networks and developing brands suited for the Latin American market. Mexico is a great example of these changes, as president-elect, Andrés Manuel López Obrador, who has the job of overseeing rule making and regulations around Mexico's new marijuana law, unveiled a plan to change the country's drug strategy in several big ways.
Colombia, another front-runner in the Latin American cannabis market, is rapidly growing its capabilities. The government is hoping to grow up to 40.5 tons of cannabis per year, which would account for approximately 44% of the licenses issued globally. Colombia is estimated to capture as much as one-fifth of the global market, a value of $40 billion a year.
"Chemesis Latin America is a big step forward in our global growth strategy," said CEO, Edgar Montero. "We believe Chemesis has a major advantage in this region, as the recent acquisition of Natural Ventures can be leveraged to quickly capitalize on upcoming opportunities. With progressive regulations, Latin America becomes a key market that will be a major part of our portfolio. The Company has positioned itself to take advantage of significant opportunities in both Mexico and Colombia. This allows Chemesis to execute on its ambitious growth strategy to identify opportunities that will build long-term shareholder value. The company plans to announce the specific countries and jurisdictions where it will be operating in the near future."
About Chemesis International Inc.: Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California. Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products. Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale."
Read more at http://www.stockhouse.com/news/press-releases/2018/09/19/dat…
C.CSI, C.MMEN, C.ICAN, CNAB, CBSHP | 1 day ago
FinancialBuzz.com News Commentary
PR Newswire
NEW YORK, September 19, 2018
NEW YORK, September 19, 2018 /PRNewswire/ --
According to a report provided by Energias Market Research, the global medical cannabis market is projected to increase in value from USD 8.28 Billion in 2017 to USD 28.07 Billion in 2024 and at a CAGR of 19.1% from 2018 to 2024. There are many significant developments that help increase the growth rate of the market, such as the increasing acknowledgment of medicinal benefits and higher demand for cannabis in the treatment of various diseases, as well as growing research and development investments. The data also shows that sales of cannabis products for recreational use are also likely to rise as California's new laws regarding recreational sales went into effect earlier this year. Chemesis International Inc. (OTC: CADMF), MedMen Enterprises Inc. (OTC: MMNFF), Integrated Cannabis Company, Inc. (OTC: ICNAF), United Cannabis Corporation (OTC: CNAB), Cannabics Pharmaceuticals Inc. (OTC: CNBX)
Canada had recently passed a nationwide legalization of recreational cannabis use, following Uruguay to become the second country to do so. According to CBC, Canada is one of only two countries, besides the Netherlands, that exports cannabis products, which allows companies in Canada to gain instant revenue from recent medical cannabis legalizations in more than 20 countries. CBC reported that the "offerings in today's Canada medical marijuana market differ little from those used recreationally - the smokable plant and, more recently, oil extracts. More than 70 companies have licenses from the federal drug regulator, Health Canada, to cultivate, produce and sell medical marijuana, with more than half those licenses granted in 2017 or 2018."
Chemesis International Inc. (OTC: CADMF) is also listed on the Canadian Securities Exchange under the ticker (CSE: CSI). Earlier last week, the Company announced, "the opening of its wholly owned subsidiary Chemesis Latin America. Through this subsidiary, the Company is exploring and completing advanced due diligence on opportunities for cultivation, production and export from the Latin American market. The Company believes it will be able to quickly gain market share in Latin America through the use of its networks and existing expertise.
Chemesis' long-term growth strategy is focused on international expansion. Globally, regulation changes are occurring for both medical and recreational cannabis, and as these changes occur, Chemesis intends to be a first mover by leveraging its existing networks and developing brands suited for the Latin American market. Mexico is a great example of these changes, as president-elect, Andrés Manuel López Obrador, who has the job of overseeing rule making and regulations around Mexico's new marijuana law, unveiled a plan to change the country's drug strategy in several big ways.
Colombia, another front-runner in the Latin American cannabis market, is rapidly growing its capabilities. The government is hoping to grow up to 40.5 tons of cannabis per year, which would account for approximately 44% of the licenses issued globally. Colombia is estimated to capture as much as one-fifth of the global market, a value of $40 billion a year.
"Chemesis Latin America is a big step forward in our global growth strategy," said CEO, Edgar Montero. "We believe Chemesis has a major advantage in this region, as the recent acquisition of Natural Ventures can be leveraged to quickly capitalize on upcoming opportunities. With progressive regulations, Latin America becomes a key market that will be a major part of our portfolio. The Company has positioned itself to take advantage of significant opportunities in both Mexico and Colombia. This allows Chemesis to execute on its ambitious growth strategy to identify opportunities that will build long-term shareholder value. The company plans to announce the specific countries and jurisdictions where it will be operating in the near future."
About Chemesis International Inc.: Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California. Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products. Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale."
Read more at http://www.stockhouse.com/news/press-releases/2018/09/19/dat…
Antwort auf Beitrag Nr.: 58.761.211 von Gibbasherkeinechance am 21.09.18 13:25:16bin mal gespannt, ob in kanada dann heute mal ein paar Gewinnmitnahmen folgen... so zum Wochenende halt
Parallelen zu FSD Pharma
Dieser Wert erinnert mich an FSD Pharma, als diese empfohlen wurden ..Bin bei 0,16 eingestiegen...War aber kaum Handel und es gab kaum.aufmerksamkeit.Denke das wird hier in paar Tagen ganz anders aussehen.. Wenn hier etwas Schwung rein wird's hier abgehen...die aktuelle Situation ist mega... 01.03.24 · globenewswire · Refined Energy |
01.03.24 · IRW Press · Refined Energy |
27.02.24 · globenewswire · Refined Energy |
10.02.24 · globenewswire · Refined Energy |
08.02.24 · globenewswire · Refined Energy |
27.01.24 · globenewswire · Refined Energy |
29.11.23 · globenewswire · Refined Energy |
13.11.23 · globenewswire · Refined Energy |
26.07.23 · IRW Press · Refined Energy |
26.07.23 · globenewswire · Refined Energy |